Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Change in Taxes (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Change in Taxes for 11 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Taxes rose 156.23% year-over-year to $1.2 million, compared with a TTM value of $1.2 million through Sep 2025, up 204.14%, and an annual FY2024 reading of -$1.6 million, down 398.2% over the prior year.
  • Change in Taxes was $1.2 million for Q3 2025 at Kiora Pharmaceuticals, up from $208020.0 in the prior quarter.
  • Across five years, Change in Taxes topped out at $1.2 million in Q3 2025 and bottomed at -$2.1 million in Q3 2024.
  • Average Change in Taxes over 5 years is $33926.2, with a median of $109275.5 recorded in 2021.
  • The sharpest move saw Change in Taxes skyrocketed 10723.0% in 2021, then tumbled 1585.03% in 2025.
  • Year by year, Change in Taxes stood at $106100.0 in 2021, then crashed by 68.43% to $33497.0 in 2022, then skyrocketed by 1479.58% to $529113.0 in 2023, then tumbled by 84.37% to $82688.0 in 2024, then surged by 1317.69% to $1.2 million in 2025.
  • Business Quant data shows Change in Taxes for KPRX at $1.2 million in Q3 2025, $208020.0 in Q2 2025, and -$225794.0 in Q1 2025.